Serum N-Glycomic Biomarkers Predict Treatment Escalation in Inflammatory Bowel Disease

Archana Shubhakar*, Bas C. Jansen, Alex T. Adams, Karli R. Reiding, Nicholas T. Ventham, Rahul Kalla, Daniel Bergemalm, Paulina A. Urbanowicz, Richard A. Gardner, Manfred Wuhrer, Jonas Halfvarson, Jack Satsangi, Daryl L. Fernandes, Daniel I.R. Spencer*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review


Biomarkers to guide clinical decision making at diagnosis of inflammatory bowel disease [IBD] are urgently needed. We investigated a composite serum N-glycomic biomarker to predict future disease course in a discovery cohort of 244 newly diagnosed IBD patients. In all, 47 individual glycan peaks were analysed using ultra-high performance liquid chromatography, identifying 105 glycoforms from which 24 derived glycan traits were calculated. Multivariable logistic regression was performed to determine associations of derived glycan traits with disease. Cox proportional hazard models were used to predict treatment escalation from first-line treatment to biologics or surgery (hazard ratio [HR] 25.9, p = 1.1 × 10-12; 95% confidence interval [CI], 8.52-78.78). Application to an independent replication cohort of 54 IBD patients yielded an HR of 5.1 [p = 1.1 × 10-5; 95% CI, 2.54-10.1]. These data demonstrate the prognostic capacity of serum N-glycan biomarkers and represent a step towards personalised medicine in IBD.

Original languageEnglish
Pages (from-to)919-932
Number of pages14
JournalJournal of Crohn's and Colitis
Issue number6
Early online date24 Jan 2023
Publication statusPublished - 1 Jun 2023


  • biomarker
  • Crohn's disease
  • N-Glycans
  • personalised treatment
  • prognosis
  • ulcerative colitis


Dive into the research topics of 'Serum N-Glycomic Biomarkers Predict Treatment Escalation in Inflammatory Bowel Disease'. Together they form a unique fingerprint.

Cite this